2016
DOI: 10.1186/s12936-016-1385-4
|View full text |Cite
|
Sign up to set email alerts
|

Using supply side evidence to inform oral artemisinin monotherapy replacement in Myanmar: a case study

Abstract: BackgroundIn 2012, alarmingly high rates of oral artemisinin monotherapy availability and use were detected along Eastern Myanmar, threatening efforts to halt the spread of artemisinin resistance in the Greater Mekong Subregion (GMS), and globally. The aim of this paper is to exemplify how the use of supply side evidence generated through the ACTwatch project shaped the artemisinin monotherapy replacement malaria (AMTR) project’s design and interventions to rapidly displace oral artemisinin monotherapy with su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(11 citation statements)
references
References 10 publications
0
11
0
Order By: Relevance
“…The results are somewhat surprising in Eastern Myanmar, given that several strategies have been implemented in this area since 2012 to contain the spread of artemisinin drug resistance [ 10 ]. One of the key strategies has been a project to remove oral AMT from the private sector and replace it with quality-assured ACT through the AMTR project.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The results are somewhat surprising in Eastern Myanmar, given that several strategies have been implemented in this area since 2012 to contain the spread of artemisinin drug resistance [ 10 ]. One of the key strategies has been a project to remove oral AMT from the private sector and replace it with quality-assured ACT through the AMTR project.…”
Section: Discussionmentioning
confidence: 99%
“…Second, as no other single brand had more than three percent of the market share, another key conclusion from this study is that currently a single product and manufacturer dominates the market. This provides an opportunity, not dissimilar from that of the situation with a key supplier identified in the Eastern part of the country several years ago [ 10 ], to target the top of the supply chain and halt further large-scale distribution of this product. Finally, while oral AMT manufacturers were limited to three countries, the wider range of brand names and one-off products, seems to suggest that oral AMT is not only being imported under official supply chains (e.g.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…There are examples in the literature of innovative strategies that have focused on general retailers and itinerant drug vendors to improve access to quality-assured ACT [24]. There is also a growing body of support for itinerant drug vendors as a means to improve home-based management of malaria [26, 27], and these mobile providers have been cited as a useful means to improve the provision of care for malaria [28].…”
Section: Discussionmentioning
confidence: 99%
“…In recognition of this widespread problem in Myanmar, an oral artemisinin monotherapy replacement project was implemented in eastern Myanmar, which aimed to remove these drugs from the market through price competition and increased availability of quality-assured artemisinin-based combination therapy (ACT ). 10,11 Despite these efforts, the recent cross-sectional surveys from the ACTwatch project still detected that oral artemisinin monotherapies were available in close to 20% of private-sector drug outlets. 12,13 Besides, the quality of the ACAs was generally not tested.…”
Section: Introductionmentioning
confidence: 99%